Phase II study of SEG101 in sickle cell disease patients with Prisprism (SPARTAN)
Clinical Trial Grant
Administered By
Medicine, Hematology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
March 18, 2020
End Date
June 30, 2024
Administered By
Medicine, Hematology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
March 18, 2020
End Date
June 30, 2024